I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Indirect comparisons of brigatinib and alectinib for front-..:
Reckamp, KL
;
Lin, HM
;
Cranmer, H
...
Future Oncology, 2022, 18 (20), pp. 2499 - 2510. , 2022
Link:
https://repository.icr.ac.uk/handle/internal/5259
RT Journal T1
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
UL https://suche.suub.uni-bremen.de/peid=base-ftinstcancerres:oai:repository.icr.ac.uk:internal_5259&Exemplar=1&LAN=DE A1 Reckamp, KL A1 Lin, HM A1 Cranmer, H A1 Wu, Y A1 Zhang, P A1 Walton, LJ A1 Kay, S A1 Cichewicz, A A1 Neupane, B A1 Fahrbach, K A1 Popat, S A1 Camidge, DR PB FUTURE MEDICINE LTD YR 2022 K1 ALK inhibitor K1 Bucher ITC K1 NSCLC K1 alectinib K1 brigatinib K1 matching-adjusted indirect comparison K1 progression-free survival K1 systematic literature review K1 Anaplastic Lymphoma Kinase K1 Carbazoles K1 Carcinoma K1 Non-Small-Cell Lung K1 Clinical Trials as Topic K1 Crizotinib K1 Disease Progression K1 Humans K1 Lung Neoplasms K1 Organophosphorus Compounds K1 Piperidines K1 Protein Kinase Inhibitors K1 Pyrimidines JF Future Oncology, 2022, 18 (20), pp. 2499 - 2510 LK http://dx.doi.org/https://repository.icr.ac.uk/handle/internal/5259 DO https://repository.icr.ac.uk/handle/internal/5259 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)